Invivyd Announces Preliminary Fourth Quarter 2024 Financial Results, Strong Revenue Growth ...
PEMGARDA™ (pemivibart) net product revenue of $13.8 million, 48% growth over Q3 2024 net product revenue of $9.3 ...
The EMBO Journal48 分钟
Type-2 innate signals are dispensable for skeletal muscle regeneration and pathology linked ...
Contrary to prior data, this study shows that neither eosinophils nor STAT6-mediated IL-4/IL-13 signaling contribute ...